David Niedrig1,2, Sarah Maechler1,3, Liesa Hoppe1, Natascia Corti1, Helen Kovari4, Stefan Russmann5,6,7,8. 1. Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland. 2. Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland. 3. drugsafety.ch, Seestrasse 221, 8700, Küsnacht, Switzerland. 4. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. 5. Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland. russmann@drugsafety.ch. 6. Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland. russmann@drugsafety.ch. 7. drugsafety.ch, Seestrasse 221, 8700, Küsnacht, Switzerland. russmann@drugsafety.ch. 8. Zurich Center for Integrative Human Physiology (ZIHP), Zurich, Switzerland. russmann@drugsafety.ch.
Abstract
PURPOSE: Some macrolide and quinolone antibiotics (MQABs) are associated with QT prolongation and life-threatening torsade de pointes (TdP) arrhythmia. MQAB may also inhibit cytochrome P450 isoenzymes and thereby cause pharmacokinetic drug interactions (DDIs). There is limited data on the frequency and management of such risks in clinical practice. We aimed to quantify co-administration of MQAB with interacting drugs and associated adverse drug reactions. METHODS: We conducted an observational study within our pharmacoepidemiological database derived from electronic medical records of a tertiary care hospital. Among all users of MQAB associated with TdP, we determined the prevalence of additional QT-prolonging drugs and risk factors and identified contraindicated co-administrations of simvastatin, atorvastatin, or tizanidine. Electrocardiographic (ECG) monitoring and associated adverse events were validated in medical records. RESULTS: Among 3444 administered courses of clarithromycin, erythromycin, azithromycin, ciprofloxacin, levofloxacin, or moxifloxacin, there were 1332 (38.7 %) with concomitant use of additional QT-prolonging drugs. Among those, we identified seven cases of drug-related QT prolongation, but 49.1 % had no ECG monitoring. Of all MQAB users, 547 (15.9 %) had hypokalemia. Forty-four MQAB users had contraindicated co-administrations of simvastatin, atorvastatin, or tizanidine and three of those related adverse drug reactions. CONCLUSION: In the studied real-life setting, we found a considerable number of MQAB users with additional risk factors for TdP but no ECG monitoring. However, adverse drug reactions were rarely found, and costs vs. benefits of ECG monitoring have to be weighted. In contrast, avoidable risk factors and selected contraindicated pharmacokinetic interactions are clear targets for implementation as automated alerts in electronic prescribing systems.
PURPOSE: Some macrolide and quinolone antibiotics (MQABs) are associated with QT prolongation and life-threatening torsade de pointes (TdP) arrhythmia. MQAB may also inhibit cytochrome P450 isoenzymes and thereby cause pharmacokinetic drug interactions (DDIs). There is limited data on the frequency and management of such risks in clinical practice. We aimed to quantify co-administration of MQAB with interacting drugs and associated adverse drug reactions. METHODS: We conducted an observational study within our pharmacoepidemiological database derived from electronic medical records of a tertiary care hospital. Among all users of MQAB associated with TdP, we determined the prevalence of additional QT-prolonging drugs and risk factors and identified contraindicated co-administrations of simvastatin, atorvastatin, or tizanidine. Electrocardiographic (ECG) monitoring and associated adverse events were validated in medical records. RESULTS: Among 3444 administered courses of clarithromycin, erythromycin, azithromycin, ciprofloxacin, levofloxacin, or moxifloxacin, there were 1332 (38.7 %) with concomitant use of additional QT-prolonging drugs. Among those, we identified seven cases of drug-related QT prolongation, but 49.1 % had no ECG monitoring. Of all MQAB users, 547 (15.9 %) had hypokalemia. Forty-four MQAB users had contraindicated co-administrations of simvastatin, atorvastatin, or tizanidine and three of those related adverse drug reactions. CONCLUSION: In the studied real-life setting, we found a considerable number of MQAB users with additional risk factors for TdP but no ECG monitoring. However, adverse drug reactions were rarely found, and costs vs. benefits of ECG monitoring have to be weighted. In contrast, avoidable risk factors and selected contraindicated pharmacokinetic interactions are clear targets for implementation as automated alerts in electronic prescribing systems.
Entities:
Keywords:
Drug interactions; Drug safety; ECG monitoring; Macrolide and quinolone antibiotics; Pharmacoepidemiology; Torsade de pointes (TdP)
Authors: David Pickham; Eric Helfenbein; Julie A Shinn; Garrett Chan; Marjorie Funk; Ann Weinacker; Jia-Ni Liu; Barbara J Drew Journal: Crit Care Med Date: 2012-02 Impact factor: 7.598
Authors: Pentti M Rautaharju; Borys Surawicz; Leonard S Gettes; James J Bailey; Rory Childers; Barbara J Deal; Anton Gorgels; E William Hancock; Mark Josephson; Paul Kligfield; Jan A Kors; Peter Macfarlane; Jay W Mason; David M Mirvis; Peter Okin; Olle Pahlm; Gerard van Herpen; Galen S Wagner; Hein Wellens Journal: J Am Coll Cardiol Date: 2009-03-17 Impact factor: 24.094
Authors: Atsushi Sorita; J Martijn Bos; Bruce W Morlan; Robert F Tarrell; Michael J Ackerman; Pedro J Caraballo Journal: J Am Med Inform Assoc Date: 2014-10-16 Impact factor: 4.497
Authors: Amit M Patel; Salimah Shariff; David G Bailey; David N Juurlink; Sonja Gandhi; Muhammad Mamdani; Tara Gomes; Jamie Fleet; Y Joseph Hwang; Amit X Garg Journal: Ann Intern Med Date: 2013-06-18 Impact factor: 25.391